Valuation: Defence Therapeutics Inc.

Market Cap 22.07M 15.49M 14.03M 12.98M 11.71M 1.46B 22.85M 156M 61.83M 780M 58.12M 56.88M 2.48B P/E 2025
-9.9x
P/E 2026 -4.09x
Enterprise Value 21.91M 15.37M 13.93M 12.89M 11.63M 1.45B 22.68M 155M 61.38M 774M 57.69M 56.47M 2.46B EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
90.28%
Yield 2025 *
-
Yield 2026 -
1 week-18.31%
Current month-17.14%
1 month-19.44%
3 months-28.40%
6 months-38.30%
Current year-59.72%
1 week 0.27
Extreme 0.27
0.34
1 month 0.27
Extreme 0.27
0.42
Current year 0.27
Extreme 0.27
0.74
1 year 0.27
Extreme 0.27
0.93
3 years 0.27
Extreme 0.27
2.89
5 years 0.27
Extreme 0.27
6.3
10 years 0.27
Extreme 0.27
8.15
Manager TitleAgeSince
Chief Executive Officer - 01/08/2026
Director of Finance/CFO 55 20/12/2024
Chief Operating Officer - 17/08/2026
Director TitleAgeSince
Chairman 53 01/08/2026
Director/Board Member - 27/09/2024
Director/Board Member - 16/09/2025
Date Insider Type Main position Quantity % Market Cap. Importance
10/22/26 A Buy

Chief Executive Officer

4,333 0.0057%
10/19/26 A Buy

Chief Executive Officer

12,000 0.0158%
9/29/26 A Option

Director

400,000 0.5278%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-18.31%-66.28%-89.79% 15.49M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.55%-1.79%+27.36%+160.80% 41B
Weighted average by Cap. -0.83%+0.20%+37.22%+162.18%

Financials

2025 2026
Net sales - -
Net income -3.52M -2.47M -2.24M -2.07M -1.87M -233M -3.65M -24.88M -9.87M -124M -9.27M -9.08M -395M -6.7M -4.7M -4.26M -3.94M -3.55M -443M -6.93M -47.3M -18.76M -237M -17.63M -17.26M -751M
Net Debt 272K 191K 173K 160K 144K 17.98M 281K 1.92M 762K 9.61M 716K 701K 30.5M -161K -113K -103K -94.88K -85.6K -10.67M -167K -1.14M -452K -5.7M -425K -416K -18.1M
Projected Income Statement - Annual - Defence Therapeutics Inc.
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Employees
-
Date Price Change Volume
13/11/26 CA$0.2900 0.00% 229,867
12/11/26 CA$0.2900 -6.45% 76,500
11/11/26 CA$0.3100 -7.46% 13,000
10/11/26 CA$0.3350 -5.63% 7,000
06/11/26 CA$0.3550 +1.43% 18,228